Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.

Methods for assessing the efficacy of internally cross-linked p53 transactivation domain-based inhibitor peptides in the treatment of pediatric cancer and methods of using such peptides to treat pediatric cancer are provided.

The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptide derived from SOD1 which can be used to inhibit formation of SOD1 amyloid-like aggregates or for production of anti-SOD1 antibodies.

The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis in a subject. The composition a peptide derived from SOD1 which can be used to inhibit formation of SOD1 amyloid-like aggregates or for production of anti-SOD1 antibodies.

Peptides that home, distribute to, target, are directed to, or accumulate in tumors, cancers, or diseased cells are disclosed. Peptides that cross the blood brain barrier and home, distribute to, target, are directed to, or accumulate in the brain and in a specific region of the brain are also disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are additionally disclosed. Such compositions can be formulated for targeted or untargeted delivery of a drug to a target region, tissue, structure or cell. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

Peptides that home, distribute to, target, are directed to, or accumulate in tumors, cancers, or diseased cells are disclosed. Peptides that cross the blood brain barrier and home, distribute to, target, are directed to, or accumulate in the brain and in a specific region of the brain are also disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are additionally disclosed. Such compositions can be formulated for targeted or untargeted delivery of a drug to a target region, tissue, structure or cell. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide.

A composition comprising a first peptide selected from tripeptide, tetrapeptide and mixtures thereof; a second peptide selected from pentapeptide, hexapeptide, and mixtures thereof; an extract from the Laminaria genus, and whey protein, and a method for stimulating collagen synthesis in skin cells.

An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative () bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 23 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.

An antimicrobial peptide and an antimicrobial peptide composition comprising the same are provided. The antimicrobial peptide and the antimicrobial peptide composition have remarkably high antibacterial activity against gram-positive (+) and gram-negative () bacteria, compared to wild-type LPcin-I having an antimicrobial ability, which consists of a sequence of 23 amino acids. Also, the antimicrobial peptide can be useful in being easily synthesized and saving production costs since the antimicrobial peptide has a smaller number of amino acids, compared to the wild-type LPcin-I.

The present invention relates to novel peptides derived from melanoma-associated antigen C2 (MAGEC2), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.